Cargando…

The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice

Toxoplasmosis is an immunologically complex disease, particularly in immunocompromised patients. Although there are several therapeutic regimens for such disease, the majority of them have many drawbacks. Therefore, it is of utmost importance to improve the current regimen in an effort to achieve a...

Descripción completa

Detalles Bibliográficos
Autores principales: Almallah, Tasneem M., Khedr, Safaa I., El Nouby, Kholoud A., Younis, Salwa S., Elazeem, Mona A., Elmehy, Dalia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006249/
https://www.ncbi.nlm.nih.gov/pubmed/36786888
http://dx.doi.org/10.1007/s00436-023-07787-6
_version_ 1784905271892508672
author Almallah, Tasneem M.
Khedr, Safaa I.
El Nouby, Kholoud A.
Younis, Salwa S.
Elazeem, Mona A.
Elmehy, Dalia A.
author_facet Almallah, Tasneem M.
Khedr, Safaa I.
El Nouby, Kholoud A.
Younis, Salwa S.
Elazeem, Mona A.
Elmehy, Dalia A.
author_sort Almallah, Tasneem M.
collection PubMed
description Toxoplasmosis is an immunologically complex disease, particularly in immunocompromised patients. Although there are several therapeutic regimens for such disease, the majority of them have many drawbacks. Therefore, it is of utmost importance to improve the current regimen in an effort to achieve a well-tolerated therapy while also enhancing the host immune response. Famous for their immunomodulatory effect, Lactobacillus delbrueckii and Lactobacillus fermentum probiotics were chosen to be evaluated in this study as an adjuvant therapy against the virulent RH Toxoplasma gondii (T. gondii) strain. Experimental mice were divided into control and treated groups. The control group was further subdivided into two groups: group I: 10 uninfected mice and group II: 20 infected untreated mice. The treated experimental group was subdivided into three groups (20 mice each); group III: sulfamethoxazole-trimethoprim (SMZ-TMP) treated, group IV: probiotics treated, and group V: SMZ-TMP combined with probiotics. The results obtained revealed that combined therapy increased survival rate and time up to 95% and 16 days, respectively, with an 82% reduction of tachyzoites and marked distortion, as detected by the scanning electron microscope (SEM). Additionally, combined therapy alleviated the severity and the extent of the inflammatory cells’ infiltration, thereby reducing hepatocyte degeneration. Intriguingly, serum IF-γ level showed a significant increase to 155.92 ± 10.12 ng/L with combined therapy, reflecting the immunological role of the combined therapy. The current results revealed that probiotics have a high adjuvant potential in alleviating the impact of toxoplasmosis. Using probiotics as a synergistic treatment to modulate conventional therapy in systemic toxoplasmosis may gain popularity due to their low cost and current availability.
format Online
Article
Text
id pubmed-10006249
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-100062492023-03-12 The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice Almallah, Tasneem M. Khedr, Safaa I. El Nouby, Kholoud A. Younis, Salwa S. Elazeem, Mona A. Elmehy, Dalia A. Parasitol Res Research Toxoplasmosis is an immunologically complex disease, particularly in immunocompromised patients. Although there are several therapeutic regimens for such disease, the majority of them have many drawbacks. Therefore, it is of utmost importance to improve the current regimen in an effort to achieve a well-tolerated therapy while also enhancing the host immune response. Famous for their immunomodulatory effect, Lactobacillus delbrueckii and Lactobacillus fermentum probiotics were chosen to be evaluated in this study as an adjuvant therapy against the virulent RH Toxoplasma gondii (T. gondii) strain. Experimental mice were divided into control and treated groups. The control group was further subdivided into two groups: group I: 10 uninfected mice and group II: 20 infected untreated mice. The treated experimental group was subdivided into three groups (20 mice each); group III: sulfamethoxazole-trimethoprim (SMZ-TMP) treated, group IV: probiotics treated, and group V: SMZ-TMP combined with probiotics. The results obtained revealed that combined therapy increased survival rate and time up to 95% and 16 days, respectively, with an 82% reduction of tachyzoites and marked distortion, as detected by the scanning electron microscope (SEM). Additionally, combined therapy alleviated the severity and the extent of the inflammatory cells’ infiltration, thereby reducing hepatocyte degeneration. Intriguingly, serum IF-γ level showed a significant increase to 155.92 ± 10.12 ng/L with combined therapy, reflecting the immunological role of the combined therapy. The current results revealed that probiotics have a high adjuvant potential in alleviating the impact of toxoplasmosis. Using probiotics as a synergistic treatment to modulate conventional therapy in systemic toxoplasmosis may gain popularity due to their low cost and current availability. Springer Berlin Heidelberg 2023-02-14 2023 /pmc/articles/PMC10006249/ /pubmed/36786888 http://dx.doi.org/10.1007/s00436-023-07787-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Almallah, Tasneem M.
Khedr, Safaa I.
El Nouby, Kholoud A.
Younis, Salwa S.
Elazeem, Mona A.
Elmehy, Dalia A.
The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice
title The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice
title_full The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice
title_fullStr The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice
title_full_unstemmed The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice
title_short The synergetic potential of Lactobacillus delbrueckii and Lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice
title_sort synergetic potential of lactobacillus delbrueckii and lactobacillus fermentum probiotics in alleviating the outcome of acute toxoplasmosis in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006249/
https://www.ncbi.nlm.nih.gov/pubmed/36786888
http://dx.doi.org/10.1007/s00436-023-07787-6
work_keys_str_mv AT almallahtasneemm thesynergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT khedrsafaai thesynergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT elnoubykholouda thesynergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT younissalwas thesynergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT elazeemmonaa thesynergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT elmehydaliaa thesynergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT almallahtasneemm synergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT khedrsafaai synergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT elnoubykholouda synergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT younissalwas synergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT elazeemmonaa synergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice
AT elmehydaliaa synergeticpotentialoflactobacillusdelbrueckiiandlactobacillusfermentumprobioticsinalleviatingtheoutcomeofacutetoxoplasmosisinmice